Natalie Charnley

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory et al. · The Lancet Oncology · 2023 · 81 citations · Full text

Medicine, Oncology, Pharmacology +11

Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy

Natalie Charnley, Ananya Choudhury, P Chesser et al. · British Journal of Cancer · 2005 · 58 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC)

Marc‐Oliver Grimm, Manuela Schmidinger, I. Duran Martinez et al. · Annals of Oncology · 2019 · 56 citations · Full text

Medicine, Immunology, Oncology +14

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 49 citations · Full text

Medicine, Oncology, Surgery +15

Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy

Natalie Charnley, Catharine West, Carolyn M. Barnett et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 47 citations

Medicine, Nuclear Medicine, Oncology +16